What's Going With WeightWatchers Stock On Wednesday?
Trump Vs Harris: Democratic Candidate Holds Narrow Lead Over Ex-president In Tightening Race, New Poll Shows
FDA Sparks Controversy With Sudden Removal Of Eli Lilly's Weight Loss Drug From Shortage List
(LLY) - Analyzing Eli Lilly's Short Interest
Eli Lilly Obesity Drug Shortage Ends Fueling Lawsuit Against FDA
10 Health Care Stocks Whale Activity In Today's Session
Economist Justin Wolfers Points To Obesity Rate Decline As Ozempic And Wegovy Spur Historic Shift In Fight Against Obesity — Has US Reached A Turning Point?
Regeneron Co-founder Warns of Harms From Weight-loss Drugs: FT
Can Novo, Lilly Take Credit for U.S. Obesity Rate Decline?
Trending Stocks This Week as Strong Jobs Report Underscore Resilience of U.S. Economy
Hims & Hers Health Asserts Demand For Its Compounded Weight Loss Offering To Continue Despite Resolved Supply Shortages
Evaluating Eli Lilly Against Peers In Pharmaceuticals Industry
England's NHS Proposes Phased Rollout of Eli Lilly's Mounjaro, Considers Digital Services to Boost Access
US regulators said eli lilly and co's weight loss miracle drug is no longer in short supply, with 'substitute' manufacturer Hims & Hers plunging more than 10% during trading.
FDA stated that eli lilly and co's two exenatide-containing GLP-1 injection Zepbound and Mounjaro have been in short supply since 2022 due to increased demand, but the shortage issue is now resolved. Industry organizations say that FDA's determination equals to pharmacies stopping the allocation and distribution of generic versions of the two drugs.
Cracking The Code: Understanding Analyst Reviews For Eli Lilly
Eli Lilly Analyst Ratings
BofA's Top 10 Growth Stocks for October
Hims & Hers Health Stock Is Tumbling Thursday: Here's Why
4 Stocks to Watch on Thursday: STZ, LLY and More
U.S. Tweaks 2025 Medicare Price Negotiation Process